TAIKO PHARMACEUTICAL CO.,LTD.
4574・Prime Market・Pharmaceuticals
Governance
The company is a company with an Audit and Supervisory Committee. There are 6 directors (of which 3 are outside directors, all serving as members of the Audit and Supervisory Committee). It has established a voluntary Nomination and Compensation Committee, chaired by an outside director. It also employs an executive officer system to separate decision-making from business execution. During the fiscal year under review, the Board of Directors met 17 times.
Risk Management
The company has established a Risk Management Committee chaired by the Representative Director and President, which meets regularly on a quarterly basis in addition to holding extraordinary sessions as needed. It maintains various regulations covering financial, operational, information, crisis, and compliance matters, and operates an internal whistleblowing system, working to mitigate risk through coordination with the Audit and Supervisory Committee and the Internal Audit Office. The company identifies and evaluates risks and opportunities, including those related to sustainability, and discussions toward identifying materiality are also underway.
Shareholder Returns
Resumed dividend payments in FY2025 (December 2025 fiscal year), with an annual dividend of ¥3.30 per share (interim ¥0, year-end ¥3.30). For FY2026 (December 2026 fiscal year), an annual dividend of ¥3.50 per share (interim ¥0, year-end ¥3.50) is forecast. The medium-term management plan targets DOE of 2.0% or higher for FY2026 (December 2026 fiscal year) and 3.0% or higher for FY2028 (December 2028 fiscal year).
Dividend Policy
The basic policy is to maintain stable dividends while ensuring shareholder returns alongside retained earnings. The medium-term management plan targets DOE (dividend on equity ratio) of 2.0% or higher for FY2026 (December 2026 fiscal year) and 3.0% or higher for FY2028 (December 2028 fiscal year). Dividends are basically paid twice a year, an interim dividend (resolved by the Board of Directors) and a year-end dividend (resolved at the general shareholders' meeting). The dividend forecast for FY2026 (December 2026 fiscal year) is an annual dividend of ¥3.50 per share (interim ¥0, year-end ¥3.50), unchanged from the most recently announced forecast.
ESG
Based on the corporate philosophy of "Independence, Symbiosis, and Creation," the company is pursuing sustainability initiatives. In the Infection Control Business, it aims to contribute to CO₂ emission reductions through low-concentration chlorine dioxide gas technology, with "Cleverin" having achieved conformity with the JSA-S1021 standard. Regarding human capital, the company achieved a 100% return-to-work rate after childcare leave and a 100% childcare leave uptake rate among male employees, and disclosed an 83% paid leave utilization rate and average monthly overtime of 11.0 hours as actual results. The company is promoting diverse recruitment methods, systematic training programs, and flexible working arrangements.
Last updated: March 24, 2026